

Fund and follow creative projects and inspirational ideas with Healthios Xchange
Take a tour...

Do you have a great idea but need additional funding?

We can help grow and fund your business with our crowd financing platform.

START A PITCH >>

Single platform serves funding needs from seed to exit

What is Crowd Finance?

What is Crowd Finance?

- “Describes the Collective Effort of Individuals who Network and Pool their Resources, Usually Via the Internet, to Support Efforts Initiated by Other People or Organizations”
- Industries with Crowd Finance Traction
 - Software
 - Gaming
 - Media

Peter Drucker, “Every few hundred years in Western history there occurs a sharp transformation...within a few short decades, society rearranges itself – its worldview; its basic values, its social and political structure; its arts; its imagination. Fifty years later, they are in a new world. And the people born then cannot even imagine the world in which their grandparents lived and into which their own parents were born.”

Joana Shield – VP EMEA Facebook, “The most important word in the Internet world today is not search; it’s share”

Crowd Finance

Platforms

Donor/Reward Crowdfunding

Donor

Reward

IamScientist

Kickstarter

Donor: Contributions given in the form of a Donation; Donors motivated by social/intrinsic aims

Reward: Contributions given in the form of a donation or pre-purchase; Customers rewarded by "Perks"

Equity Crowd Finance

JOBS Act

Title II

Title III

Title IV

Reg D

Crowdfunding

Reg A+

H/X Xchange

Seedrs

FundRise

Accredited

Non-Accredited

Non/Accredited

Contributions given in the form of equity; Investors motivated by Return on Investment (ROI)

Crowd Finance

Platforms

Venture Philanthropy

L3C

Healthios Xchange (H/X)

Venture Philanthropy:
Contributions given in the form of equity; Investor motivated by benefiting society via investing in for-profit entities

Peer to Peer Lending

Debt

SoMoLend

Peer to Peer Lending: Contribution
given in the form of loans:
Lenders motivated by desire for reward/intrinsic aims or receive interest (~at below market rates)

The “Value Void”


The Value Void

A series of irrational, systematic dysfunctions – or, “Gaps” – in global healthcare capital flows in which financing requirements and investment returns are mis-aligned at sequential points along the development pathway. These dysfunctions are irrational in that they do not reflect extraordinary risk for which investors cannot be rewarded. Therein lies immense opportunity



THE VALUE VOID

Financing Requirements \neq Investment Returns



Emerging Growth Healthcare

During the past decade, the healthcare capital markets have been transformed, as (i) the number of venture capital firms has declined by 62% and aggregate annual investments by VC's has fallen 14.8%; (ii) as the number of IPO's has collapsed by 79.2%; while, (iii) overall capital inflows into emerging growth healthcare has increased 17%; (iv) the pace of investment by Corporate Venture Capital has increased by 93%; and, (v) the amount of "dry powder" funds under management by growth & private equity firms has increased at a 29% CAGR to \$175 billion.

Key Capitalization, Valuation & Liquidity Measures	Measure	Notes
Total Enterprise Value of H/C Investments	\$ 82.3 B	<i>48.3% of Capital Deployed Remains Unrealized</i>
Aggregate Value of Investment "Realizations"	\$ 42.5 B	
Total # of Sponsor-Backed H/C Companies	5,402	<i>23.7% of Portfolio Companies created 100% of "Realizations"</i>
Sponsor-Backed Companies with "Exits"	1,295	
"Exit" Events Attributable to M&A (%)	86.4%	<i>Dominance of M&A</i>
Strategic Buyers with Enterprise Value > \$250 Million	1,982	<i>Intense Selectivity, High Uncertainty Few "Winners"</i>
M&A Transactions Per Strategic Buyer	0.564	
Ratio of Emerging Growth Companies to Strategic Buyer	2.8	
Average # Of Milestone Transactions Per EGC Prior To Exit	5.73	<i>Importance of Strategic Validation</i>
Milestone Transactions Attributable to a Strategic Nature (%)	66.9%	
Financing Events Comprised Of Syndicates Of > 0 New Investors (%)	57.3%	<i>Syndicate Risk, Capital Concentration</i>
Number of Financing Rounds (avg. per Company)	3.9	
2010 NVCA Wght.'d Avg. Pooled Gross IRR (%) for Healthcare Sector	20.9%	<i>17.7% improvement over 2006</i>
Average Investment Per Financing Round	\$13.8 M	<i>"Exit" Value As Multiple Of Total Invested Capital: 4.1 x</i>
Total Invested Capital Over Horizon (avg. per Company)	\$49.7 M	
Median M&A Enterprise Value at Liquidity	\$200.7 million	

2012 JOBS Act

Recent legislation has introduced a new paradigm in the financing of Emerging Growth healthcare companies, as the increasing prominence of the private markets will be underpinned by the “Crowd” and the deployment of advanced technologies.

Highlights

Lifts General Solicitation Ban

Issuers allowed to generally solicit investors including REG D Offerings



Significance

Issuers seeking capital from investors will be able to leverage the internet

Raises Shareholder Limits

Shareholder Cap increased from 500 to 2000



Increases investor pool without forcing companies to go Public

Lesser Restrictions On REG. A

New “REG A+” limit from \$5 Mil to \$50 Mil



Small companies can raise more capital without going public

Legalizes Crowd Funding

Non-accredited investment up to \$1 Mil



Broader investor base will increase access to capital for small financings

Funding Platforms


Simplifies online posting and investing



Kickstarter campaigns have drawn as many as 60,000 investors for \$10 Mil

Crowd Finance

According to a study by the Kaufman Foundation, there are 6 million accredited investors in the U.S., alone, yet only 10% have participated in Regulation D offerings since 2009. Healthcare ranks among the top priorities for these investors.




H/X Exchange

An online investment marketplace dedicated exclusively to the global healthcare industry. The goal of the H/X is to revolutionize healthcare capital flows by generating \$5 of **new** growth capital to support every dollar of institutional and strategic commitment.



+ *A revolutionary investment marketplace dedicated exclusively to the global healthcare industry...*



+ *... To its unique structure...*



+ *... and,
To the distinct manner in which it capitalizes itself.*

What is Healthios Xchange?

What is Healthios Xchange?

- **Healthios Xchange** assists emerging growth healthcare companies raise capital from Accredited Investors and non-dilutive financing from Foundations via the following **Crowd Finance** portals:
 - Equity - **EX.PR.E.S.S.**
 - Managed Institutional Funds, Angel-Backed Companies
 - Reg D, Venture Capital-Backed Companies
 - Non-dilutive financing – **Foundation Place**
 - L3C/Program Related Investments (PRI's)
 - “Compassionate Use” High-Net Worth Investors
- **Healthios Xchange's** easy-to-use interface facilitates private placements and partnering via:
 - eSignature/Legal Documents
 - Due Diligence/Company Scoring
 - Custodial/ePayment
 - Research/Capital Flows
 - Financial Reporting

Healthios Xchange (H/X)

Emerging Growth Healthcare Companies

Healthios Xchange (H/X)

Fund Capital Needs
throughout Company
Life Cycle

Crowd Finance Platform: "Seed to Exit"



"Seed"/Angel Financing

Non-Dilutive Financing

"Series" Round Financing

Managed Institutional Funds

L3C/PRI

Reg D Filing

Non*/Accredited Investors

Foundations

Accredited Investors

*Pending JOBS Act




Healthios Xchange (H/X) –
Crowd Finance Portal

Healthios Xchange (H/X)

H/X Combines Three Market Leading Crowd Finance Business Models

Crowd Finance Platform




What does H/X Xchange Offer Companies

- Preeminent Crowd Finance Platform Devoted to Healthcare
- Efficient way to Source Capital
 - ePayment
 - eDocument
 - Online Due Diligence
 - Community: Chat
- Access to Investor Capital
 - Accredited Investors
 - Family Offices
 - Foundations
- Compliance with SEC/FINRA
 - Healthos – Registered Broker Dealer
- Novel Funding Platforms
 - *Crowd Finance* - Managed Institutional Funds
 - \$100 - \$500K Funding Range
 - Ex.PR.E.S.S. – Venture Capital and Angel Side Cars
 - \$1MM – 5MM Funding Range

Healthios Xchange

Back Office Functionality



Ex.PR.E.S.S.

Venture-Backed Securities

Healthios Xchange (H/X)

Assist VC's with
Raising Follow-on
Capital via Side Cars

Ex.PR.E.S.S. Venture Capital Side Cars

Investment in
Venture-
Backed
Companies



Investment in
Venture
Capital Funds

"Series" Round Financing

Reg D Filings

Accredited Investors

Venture Capital Financing to Exit

Ex.PR.E.S.S. Venture-
Backed Security/Fund
Advantages for
Accredited Investors:

Strategically
Validated
Pharma Partner

Institutionally
Sponsored
(VC)

12-24 Month
Exit

Return on
Investment


Ex.PR.E.S.S Securities

VC Side Cars

Institutionally Validated Companies

Venture Capital-Backed Emerging Growth Companies

Ex.PR.E.S.S. Securities



Ex.PR.E.S.S.

Case Study – Potential Ex.PR.E.S.S. Deal

12-24 Month
Exit

Strategically
Validated
Pharma Partner

Johnson & Johnson

calibra
MEDICAL

Makers of Finesse – World's first Bolus Insulin Patch



Has been acquired by



THE UNDERSIGNED ACTED AS EXCLUSIVE
ADVISOR TO CALIBRA

healthios

Institutionally
Sponsored
(VC)

Canaan Partners

Frazier Healthcare

Intersouth Partners

Three Arch Partners

Healthios Xchange (H/X)

Assist Angels with
Raising Follow-on
Capital

Ex.PR.E.S.S. Angel Side Cars



Angel Rounds

Managed Institutional Funds

Lower
Investment
Thresholds

Diversification

Invest With
Angels

Attract Angel Investors not
Participating in Groups via
H/X's Differentiated Model,
Ex.PR.E.S.S Angel Side Cars



Angel Backed
Companies

Ex.PR.E.S.S Securities

Angel Side Cars

Foundation Place

Non-Dilutive Capital

Healthios Xchange (H/X)


Success of Kalydeco
Approval Changing
Foundation
Landscape

Kalydeco

Kalydeco™ is a new oral medication for the treatment of cystic fibrosis, approved by the U.S. Food and Drug Administration (FDA) in January 2012.

Vertex/Cystic Fibrosis
Foundation (CFF) –
Approval of Kalydeco

Kalydeco is the first drug available that targets the underlying cause of CF — a faulty gene and its protein product, CFTR.



Healthios Xchange (H/X)

Foundations
Leverage H/X to
Identify Companies

Foundation Place

Foundations

1. Leverage H/X Scoring System: Select Best Companies to Invest – Due Diligence
2. Ease-of-Use: eDocument and payment capabilities
3. Streamline Program Related Investments (PRI's): Abide by IRS Regulations



Non-Dilutive Financing

L3C/PRI's

Companies

1. Leverage H/X Scoring System: Secure Foundation/Charity Visibility and Interest
2. Ease-of-Use: eDocument and payment capabilities
3. Identify Foundations Interested in Funding Emerging Growth Life Science Companies Directly

Healthios Xchange (H/X)

Ex.PR.E.S.S and
Foundation Place –
Synergies

Ex.PR.E.S.S. and Foundation Place Portal



Foundations and Charities
Participate in VC-Backed,
Institutionally Validated
Investments, *Ex.PR.E.S.S.*




Non-Dilutive Financing

L3C/PRI's

"Series" Round Financing

Reg D Filing



Ex.PR.E.S.S. Investors with
Charitable Intent Fund *Foundation
Place* Deals

% of Foundations Investing in L3C/PRI's

2008

2011

1%

7%

Crowd Finance

Seed/Angel Investments

Healthios Xchange (H/X)

Assist Angels with
Raising Follow-on
Capital

Crowd Finance



“Seed”/Angel Financing

Managed Institutional Funds

Lower
Investment
Thresholds

Diversification

No Annual
Dues

Attract Angel Investors not
Participating in Groups via
H/X’s Differentiated Model,
Ex.PR.E.S.S Angel Side Cars



Angel Backed
Companies

Ex.PR.E.S.S Securities

Angel Side Cars

LiquidNet & InMarket

Secondary Trading & Liquidity

Healthios Xchange (H/X)

Facilitate Trading and "Exits" for Investors/Companies

InMarket & LiquidNet



Secondary Trading

Liquidity Vehicles

Trade Private Shares

Securitize Contingencies

Reverse Mergers

OTC.BB

Liquidity/"Exits"

M&A

Direct Listing Form 10

Sub 20's*


Facilitate Investor Exits via Secondary Trading and Liquidity Vehicles

Healthios Xchange (H/X)

Accredited Investor Database

Healthios Xchange (H/X)

Accredited Investor Objectives



Investors – Accredited


Sources of Capital - Database



Broker Dealers/RIAs

Raise Capital from Brokers Dealers and RIAs via H/X


Source Capital via Broker Dealers/RIAs



Source Capital - SJAConnect

Qualify Potential
Crowd Finance
Investors

Source Capital via Inbound Marketing



Source Capital via Referrals

“Empower the Crowd”

Ecosystem Members Leverage H/X to Close Banking/Business Development Engagements by Referring Companies/Investors

Ecosystem Members

Accelerators

Angels

Consultants

Large
Pharma

Venture
Capital

Referrals

Companies

Investors

H/X “Engine”

Banking

Business Development

Raise \$

License

M&A

Ecosystem members receive Lead Activity Reports:

Leads
Cycled
Back to
Ecosystem
Members

VC's

Angels

Crowd

Source Capital via Angels

Build Trust with
Angels, Reduce
Follow-on Capital
Risk

Angel Group Priority List – Most Important to Least

- #1. Reduce Follow-On Financing Risk, Raise “Side Car” Capital
- #2. Increase Memberships
- #3. Due Diligence Assistance
- #4. Deal Flow

Healthios
Xchange
(H/X) – Assist
Angels with
#1-#4
objectives

Angels & H/X – Ex.PR.E.S.S

Maximize Angel/VC investor ROI

#1 Priority: Reduce Follow-On Financing Risk




Angel Capital + “Side Car” Funds (Ex.PR.E.S.S)

Venture Capital

Angels

H/X Benefits

H/X Benefits



Angels & H/X - Members

Capture Angel Investors with Net Worth >\$10MM; <\$1MM

#2 Priority: Expand Angel Participation

Net Worth	Angel Participation	Challenges
>\$10MM	Low	Operate in Smaller Groups
<\$1MM	Low	Lower Fees/Diversification

Investors <\$1MM

Investors >\$10MM

Low Investment Thresholds

No Annual Dues

Diversification

Angel Side Car Financing, Ex.PR.E.S.S.

Investor participation in Angel-backed deals

Institutional Sponsorship

Strategic Validation

12-24 Month Exit


Venture Capital Side Cars, Ex.PR.E.S.S.

Investor access in Venture Capital-backed Deals

Angels & H/X – Due Diligence

Crowdsource Deal Flow – Improve Deal Quality


#3 Priority: Co-Sponsor Due Diligence



Angels & H/X – Deal Flow

Transition from
Angel Crowd Finance
Users to Investors


#4 Priority: Source Deal Flow



Angels Invest in H/X Sponsored Deals

Crowd Finance Highlights

Highlights



Definitions

Definitions

- **501(c)3** – American tax-exempt nonprofit organization exempt from some federal income taxes; apply to corporations, fund, cooperating association or foundation
- **Crowdfunding** – Describes the collective efforts of individuals who network and pool their money, usually via the Internet, to support efforts initiated by other people or organizations
- **Jobs Act** – Jumpstart our Business Startups Act is a law intended to encourage funding of United States' small businesses by easing securities regulations including Crowdfunding
- **L3C** – A low-profit limited liability company created to bridge the gap between non-profit and for-profit investing by providing a structure that facilitates investments in socially beneficial, for-profit ventures while simplifying compliance with Internal Revenue Service rules for program related investments
- **Managed Institutional Fund** – Proprietary Healthios Crowd Finance fund/portal for Accredited investors characterized by low investment thresholds allowing diversification
- **OTC.BB** - United States quotation medium for subscribing members used for many over-the-counter (OTC) equity securities that are not listed on NASDAQ or a national stock exchange.
- **Reg D** – Contains the rules providing exemption from the registration requirements, allowing some companies to offer and sell their securities without having to register the securities with the SEC
- **Reverse Merger** – Acquisition of a public company by a private company so that the private company can bypass the lengthy/complex process of going public
- **Seed Money** – Form of securities offering in which an investor purchases part of a business; Seed suggests this is an early investment meant to support the business until it can generate cash of its own or until it is ready for further investment
- **Side Cars** – Follow-on Capital to Angel and Venture Capital Financing Rounds; Angel/Venture Capital is “lead” capital setting valuation/terms and Accredited Investors have opportunity to participate in deal flow that is institutionally sponsored
- **Venture Philanthropy** – Takes concepts and techniques from venture capital finance and high technology business management and applies them to achieving philanthropy goals

Contact Information

Healthios Xchange (H/X)

Contact Information

Scott Jordan

1101 Skokie Boulevard

Northbrook, IL 60062

847-849-1736

sjordan@healthios.com

<http://healthios.com/>

Addendum

Potential Ex.PR.E.S.S. Deals

Healthios EX.PR.E.S.S.

Case Studies



LIQUIDIA TECHNOLOGIES, INC.

Has completed a global collaboration with



THE UNDERSIGNED ACTED AS FINANCIAL ADVISOR TO LIQUIDIA



Company	<i>Micro and nanoparticles for the delivery of biological and small molecule therapeutics</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; Strategic Validation; 24-month "Exit"</i>
Co-Investor / Lead	<i>Bill & Melinda Gates Foundation; Canaan; Firelake; Morningside; NIST; NEA; Pappas; Pharmaceutical Product Development; UNC; Velocity; Wakefield</i>
Result	<i>\$360 million partnership with Glaxo Smith Kline</i>



CORIUM INTERNATIONAL, INC.

Has issued \$35 million in Interest-Bearing High Yield Securities

THE UNDERSIGNED ACTED AS STRATEGIC ADVISOR TO CORIUM INTERNATIONAL



Company	<i>Advanced transdermal drug delivery company</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; Strategic Validation; 24-month "Exit"</i>
Co-Investor / Lead	<i>Aphelion Capital; Essex Woodlands; Quantum Technology Partners</i>
Result	<i>Partnership with Procter & Gamble, Teva Pharmaceuticals</i>

Healthios EX.PR.E.S.S.

Case Studies

ePOCRATES®

EPOCRATES, INC.

Has completed multiple strategic initiatives

THE UNDERSIGNED ACTED AS STRATEGIC ADVISOR TO EPOCRATES



Company	<i>Mobile and web-based provider of clinical information and decision support tools to healthcare professionals</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; 24-month “Exit”</i>
Co-Investor / Lead	<i>Bay City Capital,, Draper Fisher Jurvetson, Goldman Sachs, Industry Ventures, InterWest Partners, Millennium Partners, New Leaf Ventures, Sprout Group, Three Arch Partners</i>
Result	<i>IPO</i>

cardiosolutions™

CARDIOSOLUTIONS, INC.

Has completed its \$15,000,000 Series B financing led by



THE UNDERSIGNED ACTED AS EXCLUSIVE FINANCIAL ADVISOR TO CARDIOSOLUTIONS



Company	<i>Percutaneous catheter-based structural heart solution for patients with mitral regurgitation</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; Strategic Validation; 24-month “Exit”</i>
Co-Investor / Lead	<i>BioVentures; Makaira Venture</i>
Result	<i>\$250 million partnership with Sorin</i>

Healthios EX.PR.E.S.S.

Case Studies



calibra
MEDICAL

CALIBRA MEDICAL, INC.

Has been acquired by



LIFESCAN
a Johnson & Johnson company

THE UNDERSIGNED ACTED AS EXCLUSIVE FINANCIAL ADVISOR TO CALIBRA



Company	<i>Small, wearable, disposable devices, Finesse™, that deliver insulin to patients with insulin-dependent</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; 24-month “Exit”</i>
Co-Investor / Lead	<i>Canaan Partners, Frazier Healthcare Ventures, Intersouth Partners, Skyline Ventures, Three Arch Partners</i>
Result	<i>Sold to JNJ</i>



WellDoc

WELLDAC, INC.

Has completed a strategic partnership with



at&t

THE UNDERSIGNED ACTED AS STRATEGIC ADVISOR TO WELLDAC



Company	<i>Mobile and web-based chronic disease management platform technology that supports patient self-management and provider clinical decisions</i>
EX.PR.E.S.S. Rules?	<i>Strategic Validation; 24-month “Exit”</i>
Co-Investor / Lead	<i>Leading global insulin provider</i>
Result	<i>Partnership with AT&T</i>

Healthios EX.PR.E.S.S.

Case Studies



SYNCARDIA SYSTEMS, INC.

Has completed its \$11,000,000 Series D financing

THE UNDERSIGNED ACTED AS ADVISOR TO SYNCARDIA



Company	<i>The world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; 24-Month "Exit"</i>
Co-Investor / Lead	<i>Ceres Venture; Highway 12; HMA Capital; Iron Gate; Seneca Health Partners; Trinity Capital</i>
Result	<i>\$7 million EBITDA, annualized.</i>



VERAX BIOMEDICAL, INC.

Has entered a Worldwide Commercialization Partnership with



THE UNDERSIGNED ACTED AS EXCLUSIVE FINANCIAL ADVISOR TO VERAX BIOMEDICAL



Company	<i>Rapid tests for detection of bacterial contaminants in blood components, tissues for transplantation and cellular therapies</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; Strategic Validation</i>
Co-Investor / Lead	<i>BioVentures; CNF Investments; KB Partners; Long River Ventures; Sightline Partners; Teknoinvest; Village Ventures</i>
Result	<i>Partnership with Fenwal; FDA Mandate</i>

Healthios EX.PR.E.S.S.

Case Studies

BAYER PLASMA, GmbH
 An operating division of



Has been acquired by

Cerberus, LLC

THE UNDERSIGNED ACTED AS STRATEGIC
 ADVISOR TO MORGAN STANLEY



Company	<i>Blood-plasma company</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; Strategic Validation; 24-month "Exit"</i>
Co-Investor / Lead	<i>Ampersand Capital Partners (Richard Charpie), Bayer AG (DB:BAYN), Cerberus Capital Management, L.P.</i>
Result	<i>Multiple ROC: 4.0x IRR: 57.1%</i>

ING 

ING BARING

Has completed an investment in



THE UNDERSIGNED ACTED AS STRATEGIC
 ADVISOR TO ING BARING



Company	<i>Disposable medical devices mostly developed in the US, manufactured in China</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; 24-month "Exit"</i>
Co-Investor / Lead	<i>Baring Private Equity Asia; Novo Tellus Capital Partners</i>
Result	<i>Recapitalization</i>

Healthios EX.PR.E.S.S.

Case Studies



UPSTREAM REHABILITATION, LLC

Has been formed by management
in collaboration with



THE UNDERSIGNED ACTED AS STRATEGIC
ADVISOR TO UPSTREAM REHABILITATION



Company	<i>Outpatient rehabilitation therapy services provider</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; 24-month "Exit"</i>
Co-Investor / Lead	<i>Aethena Group; Charterhouse Equity Partners</i>
Result	<i>Recapitalization</i>




SXC HEALTH SOLUTIONS, INC.

Has expanded its management team and
Board of Directors with the addition of
several leaders with significant experience
in the global healthcare industry

THE UNDERSIGNED ACTED AS STRATEGIC
ADVISOR TO SXC HEALTH SOLUTIONS



Company	<i>Provide pharmacy benefit management services and healthcare information technology solutions to the healthcare benefit management industry</i>
EX.PR.E.S.S. Rules?	<i>Institutional Sponsorship; 24-month "Exit"</i>
Co-Investor / Lead	<i>ABRY Capital Partners; Arcadia Resources</i>
Result	<i>Multiple ROC: 7.8x IRR: 102%</i>



Fund and follow creative projects and inspirational ideas with Healthios Xchange
Take a tour...

Do you have a great idea but need additional funding?

We can help grow and fund your business with our crowd financing platform.

START A PITCH >>

Single platform serves funding needs from seed to exit